Skip to main content
Loading…

Chamber and committees

Questions and answers

Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.

  • Written questions must be answered within 10 working days (20 working days during recess)
  • Other questions such as Topical, Portfolio, General and First Minister's Question Times are taken in the Chamber

Urgent Questions aren't included in the Question and Answers search.  There is a SPICe fact sheet listing Urgent and emergency questions.

Find out more about parliamentary questions

Filter your results Hide all filters

Dates of parliamentary sessions
  1. Session 1: 12 May 1999 to 31 March 2003
  2. Session 2: 7 May 2003 to 2 April 2007
  3. Session 3: 9 May 2007 to 22 March 2011
  4. Session 4: 11 May 2011 to 23 March 2016
  5. Session 5: 12 May 2016 to 4 May 2021
  6. Current session: 13 May 2021 to 21 December 2025
Answer status
Question type

Displaying 46887 questions Show Answers

Order by |

Question reference: S6W-29676

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe alemtuzumab (Lemtrada) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29687

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe ponesimod (Ponvory) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29664

  • Asked by: Nicola Sturgeon, MSP for Glasgow Southside, Scottish National Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Gillian Martin on 18 September 2024

To ask the Scottish Government whether it will list the (a) nature and (b) value of each of the supply chain projects being progressed through the strategic investment model developed by the Scottish Offshore Wind Energy Council and its partners.

Question reference: S6W-29631

  • Asked by: Pam Gosal, MSP for West Scotland, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government, regarding hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorder (HSD), what discussions it has had with healthcare providers regarding (a) the development of and (b) equipping patients with high-quality self-management tools and resources early in their diagnostic journey, to encourage agency and independence in managing their condition. 

Question reference: S6W-29625

  • Asked by: Pam Gosal, MSP for West Scotland, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government what action it is taking to create a coordinated approach for the treatment and care of people with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorder (HSD).

Question reference: S6W-29677

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe Avonex (interferon beta-1a) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29690

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe teriflunomide (Aubagio) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29686

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe Plegridy (peginterferon beta 1a) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29384

  • Asked by: Jackson Carlaw, MSP for Eastwood, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 30 August 2024
  • Current Status: Answered by Neil Gray on 18 September 2024

To ask the Scottish Government whether it has carried out any form of review exercise regarding the impact of medical receptionist staff who are employed at a GP practice having to attend jury duty, both in terms of the ability of surgeries to manage a high volume of patient phone calls and digital triage requests.

Question reference: S6W-29382

  • Asked by: Stephen Kerr, MSP for Central Scotland, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 30 August 2024
  • Current Status: Answered by Fiona Hyslop on 18 September 2024

To ask the Scottish Government whether it will provide an update on when passenger ferries will run from Rosyth to mainland Europe.